Inflammation reduces HDL protection against primary cardiac risk

European Journal of Clinical Investigation

Volumn 40, Issue 6, 2010, Pages 483-489

  Corsetti, James P ^a   Gansevoort, Ron T ^b   Sparks, Charles E ^a   Dullaart, Robin P F ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular risk; CRP; HDL cholesterol; Inflammation

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COHORT STUDIES; GEOGRAPHY; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NETHERLANDS; PARTICLE SIZE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRIGLYCERIDES;

EID: 77952633500     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02287.x     Document Type: Article

References (24)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Intensive versus moderate lowering with statins after acute coronary syndromes. N Engl J Med 2004 350: 1495 1504.
2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352: 1425 1435.
3. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006 47: 2326 2331.
4. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target-a systematic review. JAMA 2007 298: 786 798.
5. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008 7: 143 155.
6. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006 187: 191 197. (Pubitemid 43817014)
7. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008 51: 49 55.
8. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol 2008 51: 634 642.
9. van Acker BAC, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJG et al. High HDL-C does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008 200: 161 167.
10. Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 2007 196: 461 468.
11. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, van der Steege G et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006 91: 3382 3388.
12. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 2005 183: 293 300.
13. Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients. Arterioscler Thromb Vasc Biol 2008 28: 548 554.
14. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, Navis G, de Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a non-diabetic population. J Am Soc Nephrol 2000 11: 1882 1888.
15. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in the general population. Circulation 2002 106: 1777 1782.
16. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT. Albuminuria assessed from first-morning-void urine samples versus 24 hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008 168: 897 905.
17. Verhave JD, Gansevoort RT, Hillege HL, Bakker SJ, de Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004 66: S18 21.
18. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285: 2486 2497.
19. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006 58: 342 374.
20. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 2006 16: 371 386.
21. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007 18: 427 434.
22. Dullaart RPF, Perton F, Kappelle PJWH, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta 2010 1801: 84 8.
23. Dullaart RPF, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ, PREVEND Study Group. High plasma lecithin: cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010 208: 537 542.
24. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. PNAS 2008 105: 12224 12229.